|Podcasts|January 6, 2011

INC Research Discusses How CROs Can Help Oncology Trials

INC Research Discusses How CROs Can Help Oncology Trials

Dr. Mike Kurman, Senior Medical Director, Oncology and Patrick Melvin, Executive Director, Oncology at INC Research discuss the barriers to oncology drug development and how CROs are uniquely positioned to help pharma improve this process.

Dr. Mike Kurman, Senior Medical Director, Oncology, INC Research

Patrick Melvin, Executive Director, Oncology, INC Research

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related to this article

© Grispb - © Grispb - stock.adobe.com

September 21st, 2026

Moving Beyond Disappointing Pilots: Scaling Adoption of AI-Enablement in Drug Development

Most AI pilots in drug development fail not from poor technology but from lack of strategic prioritization, organizational readiness, integrated data infrastructure, and disciplined governance, making success dependent on business discipline rather than technical capability.

DPHARM 2026: Why Making Technology Easier Isn't Enough for Sites

September 21st, 2026

DPHARM 2026: Why Making Technology Easier Isn't Enough for Sites

In a video interview prior to the 2026 DPHARM conference, Andrea Valente, CEO of uMotif, explains why the real technology challenge isn't usability alone—it's making it easier for patients and sites to interact more effectively with each other.

ACT Brief: Patient-Site Trust and AI Role, Platform Approach to Scale, Gene Therapy for Pediatric Disease

September 21st, 2026

ACT Brief: Patient-Site Trust and AI Role, Platform Approach to Scale, Gene Therapy for Pediatric Disease

In today's ACT Brief, we examine what patient-site relationships need most at DPHARM, how platform-based AI scales across workflows, and FDA's approval of a gene therapy for a rare childhood syndrome.

DPHARM 2026: What the Patient-Site Relationship Needs Most Right Now

September 18th, 2026

DPHARM 2026: What the Patient-Site Relationship Needs Most Right Now

In a video interview prior to the 2026 DPHARM conference, Andrea Valente, CEO of uMotif, shares what she expects to be at the center of the conversation—from building trust between patients and sites to where AI may and may not have a role in that relationship.

Scaling AI in life sciences takes more than more tools, it takes a platform that connects workflows, data and governance. Credit: Stock.Adobe.com/Grispb.

September 18th, 2026

How a Platform Approach Can Scale AI’s Impact in Life Sciences

A platform-based approach connects AI across workflows, data and governance, helping life sciences organizations move from isolated wins to real scale.

ACT Brief: Patient Voice as Methodology, AI System Bottlenecks, Regulatory Convergence on Patient Input

September 18th, 2026

ACT Brief: Patient Voice as Methodology, AI System Bottlenecks, Regulatory Convergence on Patient Input

In today's ACT Brief, we examine what genuine patient voice requires beyond buzzwords, why AI's next bottleneck is system integration not models, and how regulators across three jurisdictions are formalizing patient input requirements.

© C Davids/peopleimages.com - © C Davids/peopleimages.com - stock.adobe.com

September 17th, 2026

What "Patient Voice" Actually Requires: Beyond the Buzzword

The clinical research industry talks about patient-centeredness constantly but embeds it too late, too narrowly, and without clear ownership, and the cost shows up in enrollment failures, protocol deviations, and outcomes that don't reflect what patients actually care about.

© Kaikoro - © Kaikoro - stock.adobe.com

September 17th, 2026

Lessons from Hundreds of Clinical Trials: AI’s Successes, Gaps, and Opportunities

Why clinical development’s next AI bottleneck is not the model, but the system around it.

Trending on Applied Clinical Trials Online

How a Platform Approach Can Scale AI’s Impact in Life Sciences

Four Years After Disrupting Clinical Trial Diversity at DPHARM, Acclinate Is Back to Disrupt the Data Behind It

DPHARM 2026: What the Patient-Site Relationship Needs Most Right Now

DPHARM 2026: Why Making Technology Easier Isn't Enough for Sites

What "Patient Voice" Actually Requires: Beyond the Buzzword